Natriumoxybaat Accord (Sodium Oxybate)

Sodium oxybate acts as an agonist at GHB receptors and modulates GABA_B receptors in the central nervous system. This dual activity enhances slow‑wave sleep, leading to more restorative nocturnal sleep, which in turn diminishes cataplexy attacks and excessive daytime sleepiness associated with narcolepsy.

The appropriate dose of Natriumoxybaat Accord is individualized by the prescribing clinician based on the patient’s clinical response, tolerability, and any relevant medical conditions. Dosage adjustments are made according to professional guidelines and patient monitoring.

Safety data for sodium oxybate in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and discuss these considerations with the patient. Use is generally reserved for situations where the therapeutic advantage justifies potential exposure.

To order Natriumoxybaat Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for daytime sleepiness in narcolepsy is modafinil, which promotes wakefulness but does not address cataplexy. Sodium oxybate uniquely improves nocturnal sleep architecture and directly reduces cataplexy episodes, offering a broader symptom control profile for patients with both sleepiness and cataplexy.

Natriumoxybaat Accord should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

The medication is taken orally, typically in divided doses at night as directed by the prescriber. It is usually ingested after a light snack and before bedtime to align with the patient’s sleep schedule and maximize therapeutic benefit.

Serious risks include respiratory depression, severe hypotension, and the potential for misuse or dependence due to its classification within the GHB family. Patients should be monitored for signs of breathing difficulty, sudden drops in blood pressure, or any behavior suggesting abuse.

Individuals with known hypersensitivity to sodium oxybate, those with severe respiratory disorders such as untreated sleep‑apnea, and patients who are concurrently using alcohol or other central nervous system depressants should avoid this medication. Contraindications are confirmed by the prescribing clinician.